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Abstract
PIK3CA is the most frequently mutated gene in human papillomavirus (HPV)-associated oropharyngeal squamous cell
carcinoma (OPSCC). Prognostic implications of such mutations remain unknown. We sought to elucidate the clinical
significance of PIK3CA mutations in HPV-associated OPSCC patients treated with definitive chemoradiation (CRT). Seventy-
seven patients with HPV-associated OPSCC were enrolled on two phase II clinical trials of deintensified CRT (60 Gy intensity-
modulated radiotherapy with concurrent weekly cisplatin). Targeted next-generation sequencing was performed. Of the 77
patients, nine had disease recurrence (two regional, four distant, three regional and distant). Thirty-four patients had muta-
tion(s) identified; 16 had PIK3CA mutations. Patients with wild-type-PIK3CA had statistically significantly higher 3-year
disease-free survival than PIK3CA-mutant patients (93.4%, 95% confidence interval [CI] ¼ 85.0% to 99.9% vs 68.8%, 95% CI ¼
26.7% to 89.8%; P¼ .004). On multivariate analysis, PIK3CA mutation was the only variable statistically significantly associated
with disease recurrence (hazard ratio ¼ 5.71, 95% CI ¼ 1.53 to 21.3; P¼ .01). PIK3CA mutation is associated with worse disease-
free survival in a prospective cohort of newly diagnosed HPV-associated OPSCC patients treated with deintensified CRT.
Human papillomavirus (HPV)-associated oropharyngeal squa-
mous cell carcinoma (OPSCC) has substantially better prognosis
after curative-intent therapy than HPV-negative OPSCC (1).
Thus, deintensified therapy for HPV-associated OPSCC patients
is being actively investigated (2–4), with a goal of reducing
treatment-associated morbidity while maintaining excellent
cancer control rates. We have been evaluating a deintensified
chemoradiation (CRT) regimen (60 Gy intensity-modulated ra-
diotherapy with concurrent weekly cisplatin) in multiple
phase II clinical trials. Disease control is excellent, with 3-year
locoregional control of 100% (3,5). Although p16 status and to-
bacco pack-years allow for prognostication (1), they are not
perfect. Approximately 10–20% of HPV-associated OPSCC
patients develop a recurrence.
We used tumor sequencing results from two
deintensification trials to identify mutations that may predict
for disease recurrence. Phosphoinositide-3-kinase is an impor-
tant oncogene, and mutations in its p110a subunit (PIK3CA)
have been associated with adverse outcomes in cervical squa-
mous cell carcinoma (6). Their prognostic significance in OPSCC
is unclear. Although HPV-associated head and neck squamous
cell carcinoma tends to have fewer mutations than
HPV-negative disease (7), PIK3CA is commonly mutated in HPV-
associated OPSCC (8,9). We sought to elucidate the clinical
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significance of PIK3CA mutations in HPV-associated OPSCC
patients treated with definitive CRT.
Seventy-seven patients with HPV-associated OPSCC were
enrolled on two phase II clinical trials of deintensified CRT
(NCT02281955/NCT03077243) at Universities of North Carolina
and Florida. Inclusion criteria were as follows: age 18 years and
older, ECOG0-1, T0-3, N0-2, M0 OPSCC [AJCC-8 staging (10)], and
p16-/HPV-positive (HPV-associated). Patients received intensity-
modulated radiotherapy (total 60 Gy, 2 Gy/fraction). Patients
with TP53 mutations received 70 Gy. Concurrent chemotherapy
was weekly cisplatin 30 mg/m2 (first choice) or cetuximab
250 mg/m2 (cisplatin-ineligible). Patients with T0-2N0-1 disease
and no more than 10 pack-years received radiotherapy alone.
Treatment response was assessed by positron-emission tomog-
raphy/computed tomography 10–16 weeks post-CRT. The clini-
cal trials in this study were reviewed and approved by the
institutional review board committees. Signed and witnessed
consent was obtained from all patients.
Next-generation sequencing (NGS) of tumor samples was
performed using UNCSeq [targeted panel-based assay, >200
cancer-associated genes; described previously (11)]. Patients
with a more than 10 pack-year history were sequenced using
solid tumor mutation panel (Supplementary Table 1, available
online).
We estimated disease-free survival (DFS) using Kaplan-
Meier method and log-rank test. Clinical characteristics were
compared by t test/v2 test; statistically significant P values were
less than .05. Cox regression model is described in
Supplementary Methods (available online). Formal tests of the
proportionality of hazards were not performed because of
the number of events, but results were verified based on the
Kaplan-Meier DFS curves. All tests were two-sided, and a P
value of less than .05 was considered statistically significant.
In this prospective cohort, 77 patients had tumor sequenc-
ing. Clinical characteristics are described in Table 1. Seventy-
five patients were treated with 60 Gy deescalated CRT; two
patients with TP53 mutations received 70 Gy. Median follow-up
was 24 months. Of the 77 patients, 34 had mutation(s) identified
(16 PIK3CA, 4 PTEN, 3 KRAS, 3 FBXW7, 3 FGFR3, 2 TP53, 1 NRAS, 1
BRCA1, 1 FLT3, 1 RAD50, 1 PIK3R1, 1 EP300; Supplementary Figure
1 and Supplementary Table 1, available online). PIK3CA was the
most commonly mutated gene (20.8%). Of 16 patients, 10 had
activating mutations in helical domain (E542K, 8/16, and E545K,
2/16) (12).
TMN staging and tobacco history were similar in patients with
wild-type (WT)-PIK3CA and mutated PIK3CA (PIK3CAmut; Table 1).
Disease recurrence patterns in our cohort were similar to previous
studies (2): nine patients had recurrence (two regional-only, four
distant-only, three regional and distant). One WT-PIK3CA patient
died from chemotherapy-related respiratory failure. Overall sur-
vival did not differ between the two groups (WT ¼ 97.7%, 95% con-
fidence interval [CI] ¼ 93.3% to 100% vs PIK3CAmut ¼ 100%; P¼ .67)
(Supplementary Figure 2, available online). Five of nine patients
with recurrences had known cancer-associated mutations, all of
which were PIK3CA mutations. Patients with WT-PIK3CA had sta-
tistically significantly higher 3-year DFS (93.4%, 95% CI ¼ 85.0% to
99.9%) compared with 68.8% (95% CI ¼ 26.7% to 89.8%) for
PIK3CAmut patients (P¼ .004; Figure 1). On multivariate analysis




No. (%) No. (%) No. (%)
(N¼ 77) (n¼ 61) (n¼ 16)
Age, mean (range), y 60 (39–84) 58 (39–80) 60 (39–84) .53
Sex
Male 66 (85.7) 52 (85.2) 14 (87.5) .82
Female 11 (14.3) 9 (14.8) 2 (12.5)
Smoking history .31
Never 33 (42.9) 28 (45.9) 5 (31.3)
10 y 21 (27.3) 16 (26.2) 5 (31.3)
>10 y 23 (29.9) 17 (27.9) 6 (37.5)
Tumor stage .68
T0 5 (6.5) 4 (6.6) 1 (6.3)
T1 18 (23.4) 14 (23.0) 4 (25.0)
T2 50 (64.9) 39 (63.9) 11 (68.8)
T3 4 (5.2) 4 (6.5) 0
T4 0 0 0
Nodal stage, 7th edition (8th edition) .32
N0 6 (7.8) 5 (8.2) 1 (6.3)
N1 11 (14.3) 10 (16.4) 1 (6.3)
N2a (N1) 3 (3.9) 2 (3.3) 1 (6.3)
N2b (N1) 47 (61.0) 37 (60.7) 10 (62.5)
N2c (N2) 10 (13.0) 7 (11.5) 3 (18.8)
N3 0 0 0
Radiation dose .46
60 Gy 75 (97.4) 59 (96.7) 16 (100.0)
70 Gy 2 (2.6) 2 (3.3) 0
Concurrent chemotherapy/systemic therapy .76
Yes 66 (85.7) 52 (85.2) 14 (87.5)
No 11 (14.3) 9 (14.8) 2 (12.5)
*v2 test, two-sided P values reported. WT ¼wild-type.
accounting for age, gender, smoking, TMN stage, mutation, and re-
ceipt of chemotherapy, only PIK3CA mutation was statistically sig-
nificantly associated with disease recurrence (hazard ratio ¼ 5.71,
95% CI¼ 1.53 to 21.3; P¼ .01).
Among the PIK3CAmut patients with disease recurrence, two
had E542K mutations, two E545K mutations, and one E726K mu-
tation. Five PIK3CAmut patients with disease recurrence received
immunotherapy; three had durable responses (14–17 months;
Supplementary Table 2, available online).
Seminal previous work demonstrated PIK3CA is commonly
mutated in HPV-associated OPSCC patients (7,9,12,13). Here, we
present prospectively collected NGS data to study the clinical
significance of PIK3CA mutations in this patient population.
Consistent with previous studies (7,14), 20.8% of patients had
PIK3CA mutations. We show that PIK3CA mutation is associated
with worse DFS in HPV-associated OPSCC patients treated with
deintensified CRT.
Few studies have evaluated the prognostic significance of
PIK3CA mutations in OPSCC. Chiosea et al. (15) studied the effect
of PIK3CA, PTEN, and HRAS mutations on disease-specific sur-
vival (DSS) in a retrospective series of HPV-associated OPSCC
patients treated with surgery followed by adjuvant radiation
plus or minus chemotherapy. They found no difference in DSS
between WT-PIK3CA and PIK3CAmut patients. There are a num-
ber of possible explanations for the apparent differences be-
tween their findings and ours. One interesting difference is that
many patients in their study received trimodality therapy vs
deescalated CRT in our cohort. This suggests that PIK3CA is a
predictive biomarker because PIK3CAmut patients have worse
outcomes than WT-PIK3CA patients after deescalated CRT but
similar DSS to WT-PIK3CA patients after escalated (trimodality)
therapy (9).
In addition, PIK3CAmut patients with disease recurrences
may have been salvaged, resulting in similar long-term DSS to
WT-PIK3CA patients (15). It was recently shown that PIK3CAmut
patients with metastatic HPV-positive OPSCC have improved
survival (16). Our study does not contradict these findings, as
eight of nine patients with recurrent disease remain alive with
a median follow-up time of 15 months after recurrence.
Interestingly, all three PIK3CA mutant alleles in patients with
recurrence (E542K, E545K, E726K) have been implicated as tar-
gets of APOBEC mutagenesis and improved responses to immu-
notherapy in solid tumors (17–19). Consistent with this, three of
five PIK3CAmut patients with recurrence who were treated with
immunotherapy experienced durable clinical response in our
study. Collectively, these findings suggest that PIK3CA muta-
tions in HPV-associated OPSCC are associated with resistance to
deescalated CRT and possibly improved response to
immunotherapy.
Although our study has multiple strengths (ie, prospective
design), limitations include relatively small size. Nevertheless,
differences observed in DFS were highly statistically significant
(P< .01). Overall survival was similar between WT- and
PIK3CAmut patients but may differ with longer follow-up.
Validation in a larger cohort (eg, National Surgical Adjuvant
Breast and Bowel Project (NSABP), the Radiation Therapy
Oncology Group (RTOG), and the Gynecologic Oncology Group
(GOG)) is an important next step. Furthermore, NGS availability
in community practice may limit widespread applicability of
the study; however, liquid biopsy may mitigate this.
PIK3CA mutations may be an adverse prognostic factor in
HPV-associated OPSCC patients treated with definitive CRT.
Patients with PIK3CA mutations may not be suitable for de-
intensified therapy, and investigation of novel treatment strate-
gies, such as with integration of immune checkpoint blockade
therapy, may be appropriate.
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Figure 1. Disease-free survival in patients with WT-PIK3CA vs PIK3CA mutations.
Kaplan-Meier estimates of disease-free survival, log-rank test, two-sided
P¼ .004. WT, n¼61. PIK3CA mutation, n¼ 16. Median time to recurrence was
17.5 (4.9–25.2) months for WT-PIK3CA and 21.0 (5.6–21.2) months for patients
with PIK3CA mutations. WT ¼wild-type.
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